SHIM
GTBP icon

Stone House Investment Management’s GT Biopharma GTBP Stock Holding History

Stone House Investment Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$510 Buy
+1,251
New +$683 ﹤0.01% 813

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Stone House Investment Management's GTBP Position: Q1 2026 in Review

Stone House Investment Management opened a new position in GT Biopharma (GTBP) in Q1 2026: 1,251 shares worth $510. The stake represents ﹤0.01% of the portfolio and ranks #813 among its holdings.

42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Stone House Investment Management held 1,251 shares of GT Biopharma worth $510 as of Q1 2026.
  • GT Biopharma was a new Stone House Investment Management position in Q1 2026.
  • GT Biopharma made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #813 holding.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.